Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA

FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.

Advisory committee recommendations and a pending citizen petition may factor into FDA’s ongoing review of Amphastar Pharmaceuticals Inc.’s NDA for a nasal spray formulation of naloxone, the opioid overdose reversal agent, intended for use in non-health care settings.

Amphastar filed a new drug application (NDA) for intranasal naloxone in April, and the user fee goal date is Feb....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers